We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. IL-23 inhibitors were associated with the lowest ...

Researchers determine the clinical and demographic risk factors of paradoxical eczema as well as the overall incidence and biologic-class-specific risk factors and incidence of paradoxical eczema in ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An oral ...

The experimental monoclonal antibody brodalumab, an interleukin 17 (IL-17) receptor antagonist, achieved a 100% reduction in plaque psoriasis symptoms in twice as many patients as the commonly used ...

Please provide your email address to receive an email when new articles are posted on . JNJ-2113 is the first and only investigational targeted oral peptide that blocks interleukin-23. Patients ...

Authors describe 3 patients with cancer who were given interleukin-23 (IL-23) inhibitors for psoriasis or immune-related psoriasis. Interleukin-23 (IL-23) inhibitors may be a safe option to treat ...

Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per ...

ORLANDO -- Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an oral peptide targeting interleukin (IL)-23, a randomized study ...